Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States

• Published in: Journal of headache and pain Vol. 22; no. 1; p. 156
• Main Authors: McAllister, Peter, Lamerato, Lois, Krasenbaum, Lynda J., Cohen, Joshua M., Tangirala, Krishna, Thompson, Stephen, Driessen, Maurice, Casciano, Julian, Dotiwala, Zenobia, Mauskop, Alexander
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 20.12.2021; Springer Nature B.V; BMC
• Subjects: Adult; Aged; Antibodies, Monoclonal; Calcitonin; Calcitonin gene-related peptide; Electronic medical records; Emergency medical care; Fremanezumab; Headache; Headache frequency; Headaches; Health care; Health care resource utilization; Humans; Internal Medicine; Medical records; Medicare; Medicine; Medicine & Public Health; Migraine; Migraine Disorders - drug therapy; Migraine pain intensity; Monoclonal antibodies; Neurology; Pain Medicine; Patients; Pregnancy; Real-world efficacy; Research Article; Resource utilization; Retrospective Studies; Statistical analysis; United States; United States; United States > US; Headache frequency; Fremanezumab; Real-world efficacy; Migraine; Migraine pain intensity; Health care resource utilization
• ISSN: 1129-2369; 1129-2377
• DOI: 10.1186/s10194-021-01358-9

Background Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for migraine prevention in adults. Real-world data on the effectiveness of fremanezumab are limited. This retrospective, observational cohort study assessed patient-reported migraine symptoms, health care resource utilization (HCRU), and direct medical costs before and after fremanezumab treatment initiation. Methods Data were extracted from September 2018 through June 2020 from the Midwest component of EMRClaims+®, an integrated health services database containing > 20 million medical records from national commercial insurance claims, Medicare claims, and regional electronic medical records. Patients included in the cohort analysis were aged ≥ 18 years and were administered fremanezumab, with enrollment or treatment history for ≥ 6 months prior (pre-index) to initiating fremanezumab (index date) and ≥ 1 month after the index date (post-index), and without pregnancy or pregnancy-related encounters during the study period. Patient-reported headache frequency, migraine pain intensity (MPI), composite migraine symptoms, and HCRU were assessed pre-index and ≥ 1 month after fremanezumab initiation. Wilcoxon signed-rank tests were used to compare means of migraine symptoms and outcomes and HCRU before and after fremanezumab initiation. Results Overall, 172 patients were eligible for analysis. Of patients who self-reported ( n  = 129), 83.7% reported improvement in headache frequency or symptoms after fremanezumab treatment. Specifically, headache frequency decreased by 63% after fremanezumab initiation: mean (standard deviation) headache frequency was 22.24 (9.29) days per month pre-index versus 8.24 (7.42) days per month post-index ( P  < 0.0001). Mean MPI also decreased by 18% after fremanezumab initiation: MPI was 5.47 (3.19) pre-index versus 4.51 (3.34) post-index ( P  = 0.014). Mean emergency room (ER) visits per month decreased from 0.72 to 0.54 ( P  = 0.003), and mean outpatient visits per month decreased from 1.04 to 0.81 ( P  < 0.001). Mean hospitalizations per month decreased, but the results did not reach statistical significance ( P  = 0.095). Hospitalization and ER costs decreased, while outpatient costs increased, from pre-index to post-index, but differences were not statistically significant ( P  ≥ 0.232). Conclusions Significant reductions in headache frequency, MPI, and HCRU were observed after fremanezumab initiation in patients with migraine in a US real-world setting.